This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Basic classification information | |
|---|---|
| ICD-10 | E77.1 |
| Special Copayment Reduction code | V117 |
| Main Korean name | Sialidosis (mucolipidosis type I) |
| Synonyms | Sialidosis [Mucolipidosis I], Mucolipidosis type I, Sialidase deficiency, Neuraminidase-1 deficiency, Sialidosis, Mucolipidosis I, Neuraminidase-1 deficiency |
| 1. History | 2. Causes |
| 3. Genetics | 4. General epidemiology |
| 5. Pathophysiology | 6. Symptoms |
| 7. Signs | 8. Screening |
| 9. Diagnosis | 10. Treatment |
| 11. Prognosis | 12. Prevention |
| 13. References | |
Sialidosis is a glycoprotein storage disease caused by deficiency of lysosomal neuraminidase (sialidase). The name 'mucolipidosis type I' was used in the early 1960s to describe a group of patients resembling mucopolysaccharidosis but with normal urinary GAG excretion, and later the name came to be used as a concept encompassing a group of diseases with features of both mucopolysaccharidosis and lipidosis. The actual specific biochemical defect of sialidosis, lysosomal neuraminidase-1 deficiency, was identified in 1977 by Cantz and Gehler, followed by confirmation of increased urinary excretion of sialyl oligosaccharides liberated from glycoproteins.
Clinically, in 1978 Lowden and O'Brien established a system classifying two phenotypes according to symptom severity—Type I (non-dysmorphic, cherry-red spot/myoclonus type) and Type II (dysmorphic, severe infantile type). Cloning of the causative gene NEU1 was achieved by Bonten et al. in 1996, and various pathogenic variants have since been reported. Understanding of the pathogenesis deepened when it was found that NEU1 is stabilized in the lysosome through complex formation with cathepsin A (PPCA).
Sialidosis is caused by genetic deficiency of lysosomal sialidase (neuraminidase-1, NEU1, EC 3.2.1.18). NEU1 is responsible for cleaving sialic acid (N-acetylneuraminic acid, NANA) residues from glycoproteins and glycolipids. When this enzyme is deficient, substrates such as sialylated oligosaccharides and sialylglycopeptides accumulate within the lysosome, and their urinary excretion also increases.
NEU1 forms a multienzyme complex with cathepsin A (PPCA, coded by the CTSA gene) and beta-galactosidase (coded by the GLB1 gene) within the lysosome, and within this complex NEU1 is stabilized and activated by cathepsin A. Therefore, cathepsin A deficiency due to CTSA gene mutations causes galactosialidosis, with secondary deficiency of both NEU1 and beta-galactosidase, which must be differentiated from sialidosis.
Sialidosis is caused directly by pathogenic variants of the NEU1 gene and is inherited in an autosomal recessive manner.
The NEU1 gene is located on chromosome 6p21.33 and consists of 6 exons. More than 100 pathogenic variants have been reported so far, with missense mutations being the most common. Some variants have known correlations with phenotype. Variants such as p.F260Y and p.L270F tend to be associated with the severe Type II phenotype, while p.G243R and p.R47W are associated with the relatively milder phenotype of Type I.
Several founder mutations have been reported in Italy, and certain variants are also observed at relatively high frequency in Japan. In all patients the mode of inheritance is autosomal recessive, and the sibling recurrence risk is 25%. Prenatal diagnosis is possible by enzyme activity measurement or molecular analysis after CVS or amniocentesis. Preimplantation genetic diagnosis (PGT-M) is also an option.
Sialidosis is a very rare disease worldwide. The exact incidence is unknown, but it is estimated at about 1 in several hundred thousand births. The number of patients reported in the literature is in the hundreds. Relatively many patients have been reported in Italy, Japan, and the Middle East. Regional clustering due to founder mutations has been reported in Italy.
There is no sex difference, and it occurs equally in men and women. Type I manifests in adolescence to adulthood, while Type II includes forms with severe symptoms from the fetal period. The congenital type of Type II presents as hydrops fetalis and may lead to neonatal death. The infantile type of Type II is diagnosed in infancy to early childhood, and Type I is diagnosed from adolescence through adulthood.
The NEU1 enzyme cleaves sialic acid residues (N-acetylneuraminic acid, sialic acid) from glycoproteins and glycolipids. When the enzyme is deficient, oligosaccharides and glycopeptides bound to sialic acid cannot be degraded and accumulate within the lysosome. These substrates also show increased urinary excretion, and a characteristic excretion pattern can be identified by LC-MS/MS analysis.
NEU1 forms a multienzyme complex with cathepsin A (PPCA) and beta-galactosidase within the lysosome. This complex functions bound to the lysosomal membrane, and NEU1 activity depends on protein processing and stabilization by cathepsin A. NEU1 deficiency also affects the structural integrity of this complex and can cause a secondary decrease in beta-galactosidase activity.
Accumulation of sialyl oligosaccharides in the nervous system promotes neuronal dysfunction and apoptosis, causing neurodegeneration, ataxia, and myoclonus. In Type I (cherry-red spot/myoclonus type), lysosomal dysfunction in cerebellar-spinal circuits and retinal cells explains the main neurological symptoms. In Type II, systemic tissue involvement is prominent, with hepatosplenomegaly, skeletal abnormalities, and severe developmental delay.
Sialidosis is clinically divided into two phenotypes.
A relatively mild form with onset in adolescence or early adulthood (10–30 years). The main symptoms are progressive visual loss, macular cherry-red spot, myoclonus, ataxia, and seizures. Intellectual function is generally normal or mildly reduced. Facial features (coarse face), skeletal abnormalities, and hepatosplenomegaly are absent or very mild. Myoclonus gradually worsens and is triggered by intentional movement (action) or stimulation (reflex).
A severe form manifesting from infancy or the fetal period. The congenital type presents prenatally or in the neonatal period with hydrops fetalis, ascites, and hepatosplenomegaly. The infantile type presents within a few months after birth with coarse facies, hepatosplenomegaly, intellectual disability, seizures, and growth delay, and a macular cherry-red spot is also observed. Radiographic multiple dysostosis may also occur. Generalized severe developmental delay is characteristic.
The most characteristic ophthalmologic finding of Type I. On fundoscopy, the macula appears red and prominent by contrast with pallor of the retina surrounding the center of the macula, due to accumulation of lysosomal substrate within ganglion cells. A cherry-red spot also appears in other lysosomal storage diseases such as Tay-Sachs disease, Niemann-Pick disease, and galactosialidosis, so differential diagnosis is needed.
The most prominent neurological finding in Type I, characterized by spontaneous or stimulus-induced myoclonus, particularly affecting the large muscle groups of the limbs. Myoclonus gradually worsens and interferes with walking and daily activities. This syndrome is also called 'cherry red spot-myoclonus syndrome'.
In Type II, coarse facies, a large tongue, and a low nasal bridge are observed. In Type I, these somatic features are almost absent.
Ataxia, pyramidal tract signs (hyperreflexia, positive Babinski sign), and progressive movement disorder occur. Cerebellar atrophy may be seen on brain MRI. Hearing loss (sensorineural) may also accompany.
A newborn screening program for sialidosis has not yet been standardized. Urinary oligosaccharide analysis is the most useful first-line screening method. In the urine of patients with sialidosis, excretion of sialylated oligosaccharides is markedly increased, and can be analyzed by thin-layer chromatography (TLC) or LC-MS/MS. The characteristic urinary oligosaccharide pattern also helps differentiate from other glycoprotein storage diseases.
For Type I, when encountering an adult patient with unexplained macular cherry-red spot combined with myoclonus, a lysosomal storage disease must be suspected, and urinary oligosaccharide analysis and measurement of leukocyte sialidase activity should be performed. For Type II, sialidosis should be included in the differential diagnosis of non-immune hydrops fetalis, and enzyme testing should be performed immediately when suspected from neonatal hepatosplenomegaly and distinctive facial findings.
Galactosialidosis (PPCA deficiency) shows secondary deficiency of both sialidase and beta-galactosidase, so it is differentiated by measuring the activity of both enzymes simultaneously.
Definitive diagnosis is made by demonstrating markedly decreased sialidase (NEU1) activity in leukocytes or cultured fibroblasts. A fluorometric assay using a fluorogenic substrate (4-methylumbelliferyl-N-acetylneuraminic acid, 4-MU-NeuAc) is standard.
NEU1 gene sequencing (Sanger or NGS panel) to confirm pathogenic variants in both alleles. Essential for confirming the diagnosis, prenatal diagnosis, and prognostic counseling.
There is currently no approved specific treatment for sialidosis, and treatment centers on supportive therapy aimed at symptom relief.
In Type I, control of myoclonus is the most important treatment goal. Valproic acid is used as the first-line drug, with levetiracetam, clonazepam, piracetam, and others used as adjuncts. Benzodiazepines such as bromazepam also help reduce myoclonus. When choosing anticonvulsants, drugs that may worsen myoclonus (carbamazepine, phenytoin, vigabatrin, etc.) should be avoided.
Enzyme replacement therapy (ERT) is being studied in animal models, but has not yet entered the clinical stage. Stabilization strategies using the NEU1-PPCA complex and AAV-based gene therapy are also at the research stage.
The prognosis of sialidosis differs greatly according to phenotype. Type I follows a relatively slow course, and some patients survive for decades after diagnosis in adulthood, but progressive myoclonus and ataxia gradually degrade function through loss of ambulation, injury from falls, and dysphagia. Cognitive function tends to be relatively preserved.
The congenital type of Type II mostly leads to death in the neonatal period or early infancy. The infantile type of Type II often leads to death before the teenage years owing to severe developmental delay and progressive neurodegeneration. The main causes of death are aspiration pneumonia, respiratory failure, and heart failure. Fall injuries from myoclonus and aspiration from choking are also important causes of morbidity. Because therapeutic intervention is currently limited, prevention of complications through multidisciplinary supportive care is most important for maintaining quality of life.
Sialidosis is inherited in an autosomal recessive manner, and the core of primary prevention is genetic counseling and prenatal diagnosis. The sibling recurrence risk is 25%, and affected fetuses can be identified early through parental carrier testing and prenatal diagnosis (enzyme activity measurement or NEU1 molecular analysis after CVS or amniocentesis). Preimplantation genetic diagnosis (PGT-M) is also an option when the familial mutation has been identified.
For the congenital type of Type II, sialidosis should be included in the differential diagnosis when hydrops fetalis is found on prenatal ultrasound. For Type I patients, even after adult-onset, it is desirable to detect asymptomatic or mild affected relatives early through testing of family members (siblings) and to establish a management plan before symptom onset. After early diagnosis, prevention of complications through multidisciplinary management is the core strategy of secondary prevention.